Loading…
Loading…
how the trade-off between the lower CapEx, and potentially lower stabilized yield may offset from the tenant improvements
I wanted to see if you could touch on what drove that shift and what gives you confidence on the continued close
I was just wondering if you could bridge that change what other assets were maybe being considered
How much of the near-term or line of sight leasing is potentially for this alternate use versus life science
has that changed your outlook at all and expectations into '26
Is -- was that a one-off transaction that you're looking to maintain? Or is that something that you could see doing across other properties
I know last quarter, you had some commentary about potential benefits to occupancy, about $600,000 or 1.7%. I was curious on the update
what would turn your perspective or optimism a little bit higher, either if that's greater IPOs or different capital market movements
can you share any possible trends or catalysts that led up to this deal being able to close
will we see that starting to peak anytime soon or any insights
Does this encompass a worst-case scenario, especially in terms of what could happen in the biotech market, specifically with capital raising or within the range is there a worst case and best-case ...
do you think that that pacing of leasing within private biotech is sustainable going forward
I was curious if you can expand on your appetite for potentially doing more JVs, especially in this recap structure.
I'm curious how that maybe has influenced or even changed your thinking and timing on opportunistic life science investments going forward? If that has actually moved up the time line or if there i...
I was wondering if you could bridge between the offsetting of the vacancies with your new leasing potential dispositions and also your redevelopment that you saw? What were the benefiting factors f...
that 100,000 seems a little bit lower than potential past LOIs that we've been seeing
Can you walk through a few of the underlying assumptions within that range?
I was curious if you could outline your kind of risk list and how that compares to the beginning of the year
I've seen some recent headlines about the influx of demand for the AI companies, especially when it comes to lab spaces
Can you just speak a little bit more on the MOBs and maybe some of the tenants such as not or at least the type of tenant that chose to not renew?
how much foresight maybe left over impacts from those -- that specific bucket, would you expect to maybe weigh on the occupancy?
if you could potentially quantify that with your current pipeline if that is what you're seeing are things getting pushed out by single quarters or longer term
what would change you to a more positive expectation and performance perhaps in the back half of 2025 if there's any news or updates to be expected?
when it comes to increased M&A in the life science area, how are you seeing that either impact demand or are you seeing a different type of clientele
Curious if you can go through how this ties to your acquisition guidance, if anything has changed in how you're viewing the landscape of capital deployment
Are there any other contributing factors or initiatives going into that figure
on the rollout of Ventas OI, is that fully with all your operators currently on your SHOP platform
is there a quantifiable difference between what your pipeline is today versus what it was 1 year ago for '25
where can we potentially see this margin number move? Are you seeing additional revenue growth or margin expansion from the layering of the Ventas OI
what's your comfortability of potentially expanding that into the U.K. or in other areas as well
I was just wondering if that has to do with anything coming into the Same-Store at a higher occupancy? Or if you're seeing things in market trends right now
recently we’ve seen some unique JV structures that have been announced with other peer companies
What was some of the best operational advice that took away from those organizations
does this now frame your SNF portfolio in total as a source of funds for future disposition or future acquisitions?
I was wondering if you could discuss your decision why for the structure